๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Microbix Biosystems Inc. (TSX:MBX)
Canada flag Canada ยท Delayed Price ยท Currency is CAD
0.2750
-0.0200 (-6.78%)
Nov 20, 2026, 4:00 PM EST

Microbix Biosystems Earnings Call Transcripts

Fiscal Year 2026

  • Diagnostics growth is supported by expanded quality-control products and qualification as a supplier to five of the 10 largest diagnostics firms. FY2026 revenue is expected at CAD 16.5Mโ€“17M; Kinlytic revenue is targeted from 2028.

  • Q3 saw 17% year-over-year revenue growth, improved gross margins, and strong cash reserves. Operational efficiencies, B2C sales growth, and progress on major projects like Kinlytic and QAPs commercialization support a positive outlook for Q4.

  • Q2 saw revenues fall below breakeven due to a sharp drop in Chinese sales and delayed antigen orders, but non-China business grew and cost controls remain strong. QAPs revenues are expected to rebound, and Kinlytic's launch is on track for 2028, with a solid cash position supporting ongoing investments.

  • Q1 2026 revenue rebounded 13% sequentially to CAD 4.2 million, with net loss managed by cash reserves. Growth in QAPs and new client wins offset ongoing weakness in China, while annual revenue is targeted at CAD 18.5โ€“19 million. NCIB share buybacks continue at 15,000 shares per day.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023